Table 2. Common AEs of systemic fungal agents used to treat CAM as reported in the US Food and Drugs Administration Adverse Events Reporting System [85].

Antifungal drug*	Number of AEs^			Common AEs
	Total cases	Serious cases (including deaths)	Death cases
AmB	10,958	10,163	4,235	Drug ineffective, off-label use, pyrexia, acute kidney injury, hypokalaemia, blood creatinine increased, multiple organ dysfunction syndrome, renal impairment, condition aggravated, renal failure, dyspnoea, chills, death
Isavuconazole	659	647	250	Death, product use in unapproved infection, off-label use, drug ineffective, drug interaction, nausea, diarrhoea, infection, febrile neutropenia, pneumonia, pyrexia, Aspergillus infection, acute kidney injury
Posaconazole	3,897	3,214	992	Drug interaction, drug ineffective, death, product use in unapproved infection, off-label use, pyrexia, pneumonia, Aspergillus infection, condition aggravated, neutropenia, AE, diarrhoea, acute kidney injury
Itraconazole	10,789	10,219	1,249	Drug interaction, dermatitis, pruritus, drug ineffective, pyrexia, dyspnoea, nausea, oedema peripheral, condition aggravated, hepatic function abnormal, asthenia, urticaria, rash maculo-papular

*Drugs in generic form.

^{^}Data as of March 31, 2021.

AE, adverse event; amphotericin B; CAM, COVID-19–associated mucormycosis.